- Initiated alongside Clovis Oncology (reported here) with an Overweight rating at Morgan Stanley is Tesaro (NASDAQ:TSRO).
- Wedbush also comes to Tesaro's defense following yesterday's CRL from the FDA, hiking its price target to $166 and suggesting the name as an attractive takeout target.
- Both Clovis and Tesaro are higher by 7% on the session.